Augustina Isioma Ikusemoro: Kell vs RhD Sensitization – The Difference in RBC Destruction
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“Anti-D destroys red cells.
Anti-K stops them from being made.
That difference can change everything in fetal survival.
Most clinicians are trained to recognize RhD sensitization as a major cause of Hemolytic Disease of the Fetus and Newborn (HDFN).
But fewer appreciate that Kell sensitization can be equally — and sometimes more — dangerous.
Here’s why this matters
While RhD antibodies destroy circulating fetal red blood cells, Anti-K antibodies suppress fetal red cell production at the bone marrow level.
This means:
- RhD sensitization leads to hemolysis
- Kell sensitization leads to erythropoiesis suppression
And clinically, that distinction is critical.
In RhD HDFN, anemia develops because red cells are destroyed in the fetal spleen.
In Kell-mediated HDFN, anemia develops because red cells are never produced in adequate numbers in the first place.
The result?
- Earlier onset anemia
- Lower reticulocyte counts
- Less predictable disease progression
- Severe fetal compromise even with low antibody titers
Unlike RhD disease — where bilirubin levels often reflect severity — Kell disease can progress silently until fetal anemia becomes critical.
This is why Anti-K detection during pregnancy must always trigger enhanced fetal surveillance.
And why transfusion services must prioritize:
- K- antigen matching for sensitized patients
- Prevention of alloimmunization in women of child-bearing age
- Extended phenotype awareness beyond ABO and RhD
Because transfusion safety doesn’t stop at compatibility.
It continues with anticipation.
Blood Doki
Advancing transfusion safety through education, systems awareness, and clinical insight.”
Stay updated with Hemostasis Today.
-
Jul 6, 2026, 19:25Ambreen Kashif: Highlighting the Impact of Temporary Donor Deferrals on Donor Retention
-
Jul 6, 2026, 19:23Rob Mac Sweeney: Anticoagulation Strategies for Cardiopulmonary Bypass in Heparin-Induced Thrombocytopenia
-
Jul 6, 2026, 19:22Nthabiseng Bapela: Interpreting INR in Patients on Warfarin – A Practical Clinical Framework
-
Jul 6, 2026, 19:20Hamza Mohamed: Key Highlights from the 2026 AHA/ACC Multisociety Guideline on Acute PE
-
Jul 6, 2026, 18:58Mostafa Faisal: High PNH Type II Neutrophil Proportions Are Associated With Thrombosis
-
Jul 6, 2026, 17:57When Hematocrit Exceeds 70 Percent: Challenges in Peripheral Blood Smear Evaluation and CBC Analysis – Seema Dawood
-
Jul 6, 2026, 17:382026 ACC/AHA Multisociety Dyslipidemia Guideline: Key Updates for Vascular Specialists – Batool Abuhalimeh
-
Jul 6, 2026, 17:27Nicolas Gendron: Should Carbon Footprint Influence Therapeutic Decisions?
-
Jul 6, 2026, 17:15Sanchit Sharma։ Continuous Anticoagulation in PVT with Varices